To investigate the impact of specific HR gene expression on sensitization to LP-184 as a single agent, we selected the highly metastatic prostate cancer cell line PC3M that was resistant to PARP inhibitor (30), to create stable knockdowns of BRCA2 and ATM followed by treating them with LP-184 or PARPi olaparib. The gene discussed is PARP1; the disease is prostate carcinoma.